MedPath

Travoprost Ophthalmic Solution

These highlights do not include all the information needed to use TRAVOPROST OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for TRAVOPROST OPHTHALMIC SOLUTION.TRAVOPROST ophthalmic solution, for topical ophthalmic useInitial U.S. Approval: 2001

Approved
Approval ID

a4fac2ac-ac94-430d-8e64-f3e72b9fc24e

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 15, 2024

Manufacturers
FDA

Bryant Ranch Prepack

DUNS: 171714327

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

travoprost

PRODUCT DETAILS

NDC Product Code63629-8840
Application NumberNDA021994
Marketing CategoryC73605
Route of AdministrationOPHTHALMIC
Effective DateSeptember 15, 2021
Generic Nametravoprost

INGREDIENTS (9)

TRAVOPROSTActive
Quantity: 0.04 mg in 1 mL
Code: WJ68R08KX9
Classification: ACTIB
BORIC ACIDInactive
Code: R57ZHV85D4
Classification: IACT
PEG-40 CASTOR OILInactive
Code: 4ERD2076EF
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT
ZINC CHLORIDEInactive
Code: 86Q357L16B
Classification: IACT
SORBITOLInactive
Code: 506T60A25R
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Travoprost Ophthalmic Solution - FDA Drug Approval Details